Journal
CANCER RESEARCH
Volume 75, Issue 11, Pages 2139-2145Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-0255
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia (NH&MRC) CDF1 Fellowship
- Prostate Cancer Foundation of Australia
- Cancer Council of Queensland (CCQ)
- NH&MRC Program Grant
- NH&MRC Senior Principal Research Fellowship
- Susan Komen for the Cure
- CCQ
- NIH [P01 CA168585, R01 CA199205]
- Ressler Family Foundation
Ask authors/readers for more resources
Cancer immunotherapy may become a major treatment backbone in many cancers over the next decade. There are numerous immune cell types found in cancers and many components of an immune reaction to cancer. Thus, the tumor has manystrategies to evade an immune response. It has been proposed that four different types of tumor microenvironment exist based on the presence or absence of tumor-infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression. We review this stratification and the latest in a series of results that shed light on new approaches for rationally designing ideal combination cancer therapies based on tumor immunology. (C) 2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available